Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.69 |
| ▸ | CCR8 | P51685 | 7/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234286 | 0.88 | CCR8 (0.65) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL5229766 | 0.86 | CCR8 (0.74) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL2074176 | 0.83 | CCR8 (0.69) | CYP2D6CCR8KCNH2USP2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5307160 | 0.82 | CCR8 (0.58) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL2077078 | 0.80 | CCR8 (1.00) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL5775593 | 0.80 | CYP2D6 (0.57) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL4238747 | 0.80 | CCR8 (0.73) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL4229282 | 0.80 | CCR8 (1.00) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL5247234 | 0.80 | CCR8 (0.73) | CYP2D6CCR8KCNH2TSHRUSP2 | |
| SCHEMBL5255658 | 0.79 | CCR8 (0.72) | CYP2D6CCR8KCNH2TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118318-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | CCR8, CCR1, CCR10 | CYP2D6 1669/4885CCR8 1/4885KCNH2 3170/4885 |
| US-20090215807-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | CCR8, CCR1, CCRL2 | CYP2D6 1375/4885CCR8 1/4885KCNH2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.